Appointment of doctor and patient must see ...

Healdsburg, CA - (MARKET - September 9, 2011) - RxFilter analysis AdverseEvents "revealed significant differences in side effect risk among the four most popular drugs bisphosphonates, which are lasix 40 meq widely used to treat osteoporosis in more than 10 million patients worldwide . Of the 21 separate categories of adverse event reviews, Reclast (injection) (production Novartis) was the highest percentage of risk followed by oral medication Fosamax (of Merck). Fosamax (alendronate), which is the number one selling drug in the class seemed to be constantly associated with higher risk of adverse events than the other two oral bisphosphonates (Actonel and Boniva), none of which showed the highest risk in any of 21 adverse events categories of analysis. No other analysis of this region were conducted on post-marketing adverse events associated with bisphosphonates. Appointment of doctor and patient should consider this new information to determine their own risk-benefit scenario, when considering this class of medication. In order to meet the growing concern about the increasing number of severe side effects [atypical fractures of the femur (hip fracture unusual) and necrosis of the jaw (jaw bone death)] suffered from osteoporosis patients, Food and Drug Administration (FDA) has convened a meeting on Friday , Sept. 9, 2011 to "discuss the benefits and risks of long-term use of bisphosphonates for the treatment and prevention of osteoporosis (thinning and weakening of bones, which increases the chance to have a broken bone) that may be associated with long-term use of bisphosphonates."

Frequency of serious adverse events in connection with wide designated osteoporosis medications is growing steadily. Regulatory authorities could not provide data that are easy to obtain, use and analyze. With the launch platform RxFilter AdverseEvents, however, as only vague information Side Effects FDA, Reporting System (AERS) is now available for review and act on, which allows to determine risk to health faster than ever before. Osteoporosis is a widespread disease that is associated with low bone density and mass, which leads to an increased risk of fractures. Drugs with a class known as bisphosphonates have been used to reduce the frequency of fractures in patients at risk. The most popular are the bisphosphonates Fosamax (alendronate), Actonel (ryzedronat), Reclast (zoledronovoyi acid) and Boniva (ibandronat). These drugs are widely prescribed to patients with osteoporosis due to their great record of effectiveness. However, due to the fact that these drugs remain active in patients for many years after taking the drug, many of the side effects associated with these compounds may not be properly captured at one time limited test phase clinical trial. Continued detailed monitoring of post-marketing adverse events associated with FDA-approved bisphosphonates is vital. RxFilter, powerful database and search tool designed AdverseEvents, was used to perform a comprehensive analysis of bisphosphonates-related adverse event case reports found in the database FDA AERS. Drugs included cases that reported to the FDA during the seven-year period from January 1, 2004 through December 31, 2010. Bisphosphonates drugs were considered: Fosamax, Actonel, Reclast and bonds, but also included general equivalents and foreign characters. Advanced Search AERS database and related forms of reporting the case was conducted to identify potentially important drug side effects associated with particular emphasis on current problems, such as the FDA atypical fractures of the femur, necrosis of the jaw, jaw fractures, and renal failure . After approval adverse event analysis of RxFilter platform in large, after approval of the drug user population suggests that serious adverse effects of bisphosphonates may be more general, which is being valued, and that the drugs in the class show diverse rates of risk. Hips and fractures of the jaw bone death, renal failure, bone infections, and various disorders of muscles and tendons of serious side effects associated with the drug class bisphosphonates selling drugs used to treat osteoporosis (Fosamax, Actonel, Reclast and Boniva ). These side effects seem to be on the consumer population is that many do not fully manifested to a year after beginning treatment bisphosphonates. In this regard, a significant delay, it is likely that these side effects have not been properly evaluated during the limited clinical testing phase associated with each drug. Prospective studies, however, necessary to establish the exact incidence rate of these side effects. This analysis deserves the attention of all health care providers and patients associated with bisphosphonates and other bone resorptive anti-drugs. About AdverseEvents, Inc AdverseEvents, Inc (AEI) is the first operator, provide accurate, real-time information about drug side effects reported by FDA. AEI uses a unique data source method RxFilter, own 17-step data refinement process that standardizes and normalizes the data with side effects of FDA, reporting system (AERS) in a convenient, with a searchable database of over 4000 approved drugs. More than 500,000 treatment side effects are reported annually in the FDA, it is estimated that only 10% of all real side effects. As a leading resource for the pharmaceutical industry, AEY supports companies with competitive intelligence and data to inform drug marketing solutions and business development strategies. From the AEI, the medical industry can provide quantitative estimates of benefit and risk assessment of FDA approved drugs to fully understand the scale of security based on the exact rate of side effects of drugs. For more information about side effects, please visit. .